TREATMENT OF METASTATIC COLORECTAL CANCER

Shchepotin I.B., Kolesnik Y.A.

Data on the results of surgery treatment of colorectal cancer patients with metastases in the liver and lung are presented as well as findings of randomized studies of the efficacy of drug treatment of patients with metastatic colorectal cancer (MCRC). Progressive application of the two most active modern regimens of combined chemotherapy (FOLFOX, FOLFIRI) resulted in an overall survival of about 20 months. The paper discusses existing chemotherapy regimens in combination with drugs of targeted molecular action such as MAbs to receptors of vascular endothelial growth factor (bevacizumab) and epidermal growth factor (cetuximab). In patients with progressive disease, resistance to irinotekan and oxaliplatin can be overcome through simultaneous application of the drugs with MAbs. In BOND-2 study, a combination of MAb — bevacizumab and cetuximab with FOLFOX and FOLFIRI regimens in MCRC patients (n = 2300) was studied. The overall survival rate increased to 27,5 months.